 |
|
|
|
Femprox®
Femprox® (alprostadil and DDAIP HCl for treatment of Female Sexual Arousal Disorder; 1 Phase III completed and Pre-NDS meeting scheduled in Canada)
To the company’s knowledge no product is currently approved to treat female sexual arousal disorder, a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress.
Femprox® exerts a relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow. This leads to pelvic engorgement and enhanced secretion activity of the vulvar epithelium. The resultant increase in lubrication and sensory feedback due to pelvic engorgement is believed to produce a clinically significant increase in sexual arousal in women with FSAD. Apricus Bio's Femprox® enables a rapid permeation of blood deep into the target tissues thus enabling a new pharmacotherapy for the treatment of FSAD through increasing the blood flow to tissue.
|
|
|
|
| |
|
|
|
Phase 3 stage